Biogen CEO granted 38,015 RSUs

Viehbacher Christopher reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Viehbacher Christopher reported acquisition or exercise transactions in this Form 4 filing.

BIOGEN INC. reported that President and CEO Christopher Viehbacher received a grant of 38,015 restricted stock units on February 13, 2026. These units are a form of equity compensation and were awarded at a stated price of $0.00 per unit.

The restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the grant date of February 13, 2026. This means the award is structured to vest over three years, aligning the CEO’s compensation with longer-term company performance.

Insider Trade Summary

Grant/Award: 38,015 shares

Grant/Award 1 txn

Insider Viehbacher Christopher

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	38,015	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 38,015 contracts (Direct)

Footnotes (1)

1. F1. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BIOGEN INC. (BIIB) report for Christopher Viehbacher?

BIOGEN INC. reported that President and CEO Christopher Viehbacher received a grant of 38,015 restricted stock units. The award was recorded at a price of $0.00 per unit as part of his equity-based compensation on February 13, 2026.

How many restricted stock units were granted to the BIOGEN (BIIB) CEO?

Christopher Viehbacher was granted 38,015 restricted stock units of BIOGEN INC. stock. These units represent a contingent right to receive shares, subject to the vesting schedule described in the filing and continued service or other award conditions, if any.

When do Christopher Viehbacher’s BIOGEN (BIIB) restricted stock units vest?

The restricted stock units vest in three equal yearly installments. Vesting begins on the first anniversary of the February 13, 2026 grant date, with additional installments on the following two anniversaries, aligning the award with a three-year timeframe.

Was the BIOGEN (BIIB) CEO’s restricted stock unit grant a purchase or an award?

The transaction is characterized as a grant or award acquisition of restricted stock units, coded as an “A” transaction. It reflects equity compensation rather than an open-market purchase, with a stated grant price of $0.00 per unit according to the filing.

How many derivative securities does the BIOGEN (BIIB) CEO hold after this grant?

Following the grant of 38,015 restricted stock units, the total number of these derivative securities reported as owned directly by Christopher Viehbacher is 38,015. This figure reflects his reported holdings of the granted restricted stock units after the award.

What does the Form 4 mean for BIOGEN (BIIB) executive compensation?

The Form 4 shows that BIOGEN INC.’s President and CEO received a time-based restricted stock unit award. The three-year vesting schedule beginning February 13, 2026 ties a portion of his compensation to the company’s longer-term share performance and retention.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 08:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Viehbacher Christopher

(Last) (First) (Middle)

BIOGEN INC.

225 BINNEY

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	02/13/2026		A		38,015		(1)	02/13/2029	Common Stock	38,015	$0	38,015	D

Explanation of Responses:

1. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.

	/s/ Wendell Taylor, attorney-in-fact for Christopher A. Viehbacher	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.